Hengrui Medicine’s SHR-1802 + SHR-1316 Combo Receives NMPA Approval for Solid Tumor Study
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that it has received approval from...
Betta Pharmaceuticals Enrolls First Patient in BPI-442096 Phase I Study for Solid Tumors
China-based Betta Pharmaceuticals (SHE: 300558) announced that the first subject has been enrolled in a...
Hengrui Medicine’s SHR-A1811 Combo Receives NMPA Approval for HER2+ NSCLC Study
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that it has received approval from...
Ascentage Pharma Launches Olverembatinib Named Patient Program with Tanner Pharma
China-based Ascentage Pharma (HKG: 6855) announced the launch of a Named Patient Program (NPP) for...
Sirnaomics’ STP705 Receives Approval for Liver Cancer Trial in Taiwan
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) announced that it has received approval from...
GenFleet Therapeutics’ GFH018 Receives CTA Approval for Two Clinical Trials in China
Shanghai-based biotech company GenFleet Therapeutics announced that two clinical trial applications (CTAs) for its drug...
NMPA Approves Genuine Biotech’s Azvudine for COVID-19, Fosun Pharma Inks Licensing Deal
China’s National Medical Products Administration (NMPA) has conditionally approved HeNan Genuine Biotech Co., Ltd’s azvudine...
Chinese Pharmacists Association Releases Draft VBP Drug Management Guidelines for Public Feedback
The Chinese Pharmacists Association (CPA) has released the “National Volume-based Procurement (VBP) Drug Management Expert...
3D Medicines Files IPO Prospectus for Hong Kong Listing
China-based oncology specialist 3D Medicines has published its initial public offering (IPO) prospectus with the...
I-Mab Doses First Patient in Global Phase I Study for TJ-CD4B in Solid Tumors
I-Mab (NASDAQ: IMAB), a Nasdaq-listed company since 2020, announced that the first patient has been...
Rona Therapeutics Licenses Sanofi’s siRNA Platform for Global Development
Shanghai-based RNA therapeutics specialist Rona Therapeutics has entered into a licensing agreement with French pharmaceutical...
ApolloBio Corp. Initiates Pre-Clinical Study for ABC-5100 Nanobody Against COVID-19
ApolloBio Corp. (NEEQ:430187) announced the initiation of a pre-clinical study for its novel broad-spectrum anti-COVID-19...
InventisBio Raises USD 308M in Shanghai STAR IPO, Valued at USD 1.54B
China-based biotech firm InventisBio (SHA: 688382) has completed an initial public offering (IPO) of 115...
NMPA Releases 56th Batch of GQCE Reference Drugs, Including 14 Injectables
The National Medical Products Administration (NMPA) has released the 56th batch of reference drugs for...
MobiDrop Raises USD 14.8M in Series A+ to Expand Single-Cell Product Pipeline
China-based MobiDrop (Zhejiang) Co., Ltd has reportedly raised close to RMB 100 million (USD 14.8...
Luye Pharma’s LY01005 Meets Phase III Trial Goals in Breast Cancer Treatment
China-based Luye Pharma Group (HKG: 2186) announced that its Phase III clinical study for LY01005...
ZGC Shuimu Medtech Raises RMB 100M in Series A+ Round Led by Yijing Capital
Beijing-based ZGC Shuimu Medical Technology Services Group, China’s first private third-party medical device testing institution,...
Innovita Biological Technology’s IPO Raises USD 131.3M for POCT Expansion
Innovita Biological Technology Co., Ltd, a Beijing-based point-of-care testing (POCT) specialist, is set to make...
Fidia Farmaceutici’s Hyalubrix 60 Shows Promise in Treating Arthropathy at Hainan Hospital
Italy-based Fidia Farmaceutici S.p.A announced that its Hyalubrix 60, a prefilled syringe with sodium hyaluronate...
Linno Pharmaceuticals Raises USD 14.78M for Blood-Brain Barrier Drug Delivery Tech
Shanghai-based rare disease specialist Linno Pharmaceuticals Inc. has reportedly raised close to RMB 100 million...